Caffeine for Apnea of Prematurity-Sleep (CAP-S) Study
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
Apnea of prematurity is a common condition that is usually treated with methylxanthines.
Methylxanthines are adenosine receptor blockers that have powerful influences on the central
nervous system. However, little is known about the long-term effects of methylxanthines on
the developing brain.
The Caffeine for Apnea of Prematurity-Sleep (CAP-S) Study is a sub-study of the main Caffeine
for Apnea of Prematurity (CAP) trial, an international placebo-controlled randomized trial of
methylxanthine therapy for apnea of prematurity. This sub-study is designed to take advantage
of this cohort of ex-premature, 5-7 year old children who were randomized at birth to receive
either caffeine or placebo, and are currently receiving detailed neurocognitive and
behavioral assessments in the CAP trial.
Phase:
Phase 3
Details
Lead Sponsor:
McMaster University
Collaborators:
Canadian Institutes of Health Research (CIHR) National Heart, Lung, and Blood Institute (NHLBI)